JP2010527982A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010527982A5 JP2010527982A5 JP2010508910A JP2010508910A JP2010527982A5 JP 2010527982 A5 JP2010527982 A5 JP 2010527982A5 JP 2010508910 A JP2010508910 A JP 2010508910A JP 2010508910 A JP2010508910 A JP 2010508910A JP 2010527982 A5 JP2010527982 A5 JP 2010527982A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- atm
- dna
- acceptable salt
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100000648 ATM Human genes 0.000 description 7
- 108060006202 ATM Proteins 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 description 2
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 102100019696 CHKA Human genes 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 206010017758 Gastric cancer Diseases 0.000 description 1
- 210000003494 Hepatocytes Anatomy 0.000 description 1
- 208000007766 Kaposi Sarcoma Diseases 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010025650 Malignant melanoma Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010025310 Other lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 210000000496 Pancreas Anatomy 0.000 description 1
- 102000030951 Phosphotransferases Human genes 0.000 description 1
- 108091000081 Phosphotransferases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000005216 brain cancer Diseases 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000012820 cell cycle checkpoint Effects 0.000 description 1
- 210000004027 cells Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 201000011231 colorectal cancer Diseases 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000000261 vasodilator Effects 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Description
癌の処置への可能性がある前臨床試験中の一つの特定のクラスの治療剤は、ＡＴＭ(血管拡張性失調症変異)の阻害剤である。ＡＴＭは、ＤＮＡ二本鎖切断(ＤＳＢ)の検出における重要なタンパク質であり、この情報の細胞サイクル機構へのシグナル伝達はキナーゼＡＴＭ(血管拡張性失調症変異)である(Durocher and Jackson (2001) DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr Opin Cell Biol., 13:225-31, Abraham (2001) Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev., 15; 2177-96)。
発明の詳細な説明
本発明は、ＣＨＫ阻害剤、またはその薬学的に許容される塩と、ＡＴＭ阻害剤、またはその薬学的に許容される塩を含む組み合わせ物に関する。この組み合わせ物は癌の処置または予防のための方法において有用である。癌の例は、食道癌、骨髄腫、肝細胞、膵臓、頚部癌、ユーイング(ewings)腫瘍、神経芽腫、カポジ(kaposis)肉腫、卵巣癌、乳癌、結腸直腸癌、前立腺癌、膀胱癌、黒色腫、肺癌 − 非小細胞肺癌(ＮＳＣＬＣ)、および小細胞肺癌(ＳＣＬＣ)、胃癌、頭頚部癌、脳の癌、腎臓癌、リンパ腫および白血病を含む。
本発明は、ＣＨＫ阻害剤、またはその薬学的に許容される塩と、ＡＴＭ阻害剤、またはその薬学的に許容される塩を含む組み合わせ物に関する。この組み合わせ物は癌の処置または予防のための方法において有用である。癌の例は、食道癌、骨髄腫、肝細胞、膵臓、頚部癌、ユーイング(ewings)腫瘍、神経芽腫、カポジ(kaposis)肉腫、卵巣癌、乳癌、結腸直腸癌、前立腺癌、膀胱癌、黒色腫、肺癌 − 非小細胞肺癌(ＮＳＣＬＣ)、および小細胞肺癌(ＳＣＬＣ)、胃癌、頭頚部癌、脳の癌、腎臓癌、リンパ腫および白血病を含む。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94024307P | 2007-05-25 | 2007-05-25 | |
| PCT/GB2008/050373 WO2008146036A1 (en) | 2007-05-25 | 2008-05-23 | Combination of checkponit kinase ( chk) and telangiectasia mutated (atm) inhibitors for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010527982A JP2010527982A (ja) | 2010-08-19 |
| JP2010527982A5 true JP2010527982A5 (ja) | 2011-07-07 |
Family
ID=39689481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010508910A Pending JP2010527982A (ja) | 2007-05-25 | 2008-05-23 | 癌の処置のためのチェックポイントキナーゼ（ｃｈｋ）および毛細血管拡張性変異（ａｔｍ）阻害剤の組み合わせ物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100240645A1 (ja) |
| EP (1) | EP2164485A1 (ja) |
| JP (1) | JP2010527982A (ja) |
| CN (1) | CN101827591A (ja) |
| WO (1) | WO2008146036A1 (ja) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6348311B1 (en) * | 1999-02-10 | 2002-02-19 | St. Jude Childre's Research Hospital | ATM kinase modulation for screening and therapies |
| WO2005066163A2 (en) * | 2004-01-05 | 2005-07-21 | Astrazeneca Ab | Thiophene derivatives as chk 1 inihibitors |
| AU2006203963A1 (en) * | 2005-01-06 | 2006-07-13 | Merck Sharp & Dohme Corp. | Inhibitors of checkpoint kinases |
| UY29774A1 (es) * | 2005-08-31 | 2007-03-30 | Kudos Pharm Ltd | Inhibidor de atm |
| US8030004B2 (en) * | 2005-12-06 | 2011-10-04 | Oregon Health & Science University | Cell free screening assay and methods of use |
-
2008
- 2008-05-23 JP JP2010508910A patent/JP2010527982A/ja active Pending
- 2008-05-23 EP EP08750768A patent/EP2164485A1/en not_active Withdrawn
- 2008-05-23 CN CN200880025671A patent/CN101827591A/zh active Pending
- 2008-05-23 US US12/601,332 patent/US20100240645A1/en not_active Abandoned
- 2008-05-23 WO PCT/GB2008/050373 patent/WO2008146036A1/en active Application Filing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL300937I2 (nl) | Niraparib, of een tautomeer daarvan, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder het tosylaat of een hydraat, meer in het bijzonder het tosylaat monohydraat | |
| PH12018500792A1 (en) | Benzolactam compounds as protein kinase inhibitors | |
| NO2022022I1 (no) | Fedratinib, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable hydrate thereof, in particular fedratinib dihydrochloride monohydrate | |
| CY1113930T1 (el) | Ενωσεις χρησιμες στην αναστολη της chk1 | |
| TW200607505A (en) | Fused heterocyclic kinase inhibitors | |
| UA95934C2 (ru) | Производные пиридиазинона для лечения опухолей | |
| CY1114925T1 (el) | Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης | |
| USD764468S1 (en) | Card reading and writing apparatus | |
| JP2010507577A5 (ja) | ||
| MY164480A (en) | Inhibitors of akt activity | |
| SG10201807838SA (en) | Determining cancer aggressiveness, prognosis and responsiveness to treatment | |
| MX2007009807A (es) | Agentes terapeuticos de aptameros utiles en el tratamiento de trastornos relacionados con el complemento. | |
| NZ603478A (en) | 2 -aminopyridine derivatives useful as inhibitors of atr kinase | |
| SG178866A1 (en) | Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels | |
| CO6710911A2 (es) | ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino. | |
| ATE432281T1 (de) | Pyrrolotriazin-kinasehemmer | |
| ATE513549T1 (de) | Ortho-kondensierte pyridin- und pyridimidin- derivate (z.b. purine) als proteinkinase-hemmer | |
| CY1115357T1 (el) | Χρηση αναστολεων πεπτιδιου του μονοπατιου μεταγωγης σηματος jnk οι οποιοι διαπερνουν τα κυτταρα για τη θεραπευτικη αγωγη διαφορων νοσηματων | |
| TW200633704A (en) | N-substituted benzimidazolyl c-kit inhibitors and combinatorial benzimidazole library | |
| TW200801008A (en) | Protein kinase inhibitors | |
| WO2008094575A3 (en) | 1-h-pyrazolo(3,4b)pyrimidine derivatives and their use as modulators of mitotic kinases | |
| IT1391619B1 (it) | Metodo per l'individuazione, selezione e analisi di cellule tumorali | |
| Tadesse et al. | The promise and current status of CDK12/13 inhibition for the treatment of cancer | |
| ATE402154T1 (de) | Monohydrochloridsalz von 1-ä3-ä3-(4- chlorphenyl)propoxyüpropylüpiperidin | |
| DE602007004333D1 (de) | Inhibitoren von akt (proteinkinase b) |